NASDAQ:STOKStoke Therapeutics Stock Price, Forecast & News

Stoke Therapeutics' stock was trading at $19.73 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, STOK stock has increased by 47.0% and is now trading at $29.00.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Stoke Therapeutics.

Stoke Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Stoke Therapeutics.

Stoke Therapeutics (NASDAQ:STOK) announced its quarterly earnings results on Monday, August, 10th. The company reported ($0.39) EPS for the quarter, missing the Zacks' consensus estimate of ($0.35) by $0.04.
View Stoke Therapeutics' earnings history.

6 equities research analysts have issued 1 year price objectives for Stoke Therapeutics' shares. Their forecasts range from $30.00 to $46.00. On average, they anticipate Stoke Therapeutics' share price to reach $36.80 in the next twelve months. This suggests a possible upside of 26.9% from the stock's current price.
View analysts' price targets for Stoke Therapeutics.

News headlines about STOK stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Stoke Therapeutics earned a media sentiment score of -2.7 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Stoke Therapeutics.

Stoke Therapeutics saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 2,340,000 shares, an increase of 13.0% from the January 31st total of 2,070,000 shares. Based on an average daily volume of 158,700 shares, the short-interest ratio is currently 14.7 days. Approximately 15.1% of the shares of the company are sold short.
View Stoke Therapeutics' Short Interest.

Some companies that are related to Stoke Therapeutics include Nektar Therapeutics (NKTR), Arena Pharmaceuticals (ARNA), Global Blood Therapeutics (GBT), Biohaven Pharmaceutical (BHVN), ChemoCentryx (CCXI), Reata Pharmaceuticals (RETA), BridgeBio Pharma (BBIO), GW Pharmaceuticals PLC- (GWPH), PTC Therapeutics (PTCT), Opko Health (OPK), Insmed (INSM), Axsome Therapeutics (AXSM), Alkermes (ALKS), Agios Pharmaceuticals (AGIO) and Principia Biopharma (PRNB).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), LogicBio Therapeutics (LOGC), Alector (ALEC), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), NVIDIA (NVDA), Precision BioSciences (DTIL), Paypal (PYPL) and Sorrento Therapeutics (SRNE).

(STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Stoke Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Cormorant Asset Management LP (5.12%), Gilder Gagnon Howe & Co. LLC (4.73%), Vanguard Group Inc. (3.85%), FMR LLC (2.32%), Artal Group S.A. (0.86%) and Goldman Sachs Group Inc. (0.43%). Company insiders that own Stoke Therapeutics stock include Apple Tree Partners Iv, LP, Barry Ticho, Gene Liau, Huw M Nash, Robin A Walker and Rtw Investments, Lp.
View institutional ownership trends for Stoke Therapeutics.

STOK stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Cormorant Asset Management LP, Bank of New York Mellon Corp, American International Group Inc., and Ameritas Investment Partners Inc.. Company insiders that have sold Stoke Therapeutics company stock in the last year include Barry Ticho, Gene Liau, Huw M Nash, Robin A Walker, and Rtw Investments, Lp.
View insider buying and selling activity for Stoke Therapeutics.

STOK stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., FMR LLC, Goldman Sachs Group Inc., Artal Group S.A., SG Americas Securities LLC, Athanor Capital LP, California Public Employees Retirement System, and Swiss National Bank. Company insiders that have bought Stoke Therapeutics stock in the last two years include Apple Tree Partners Iv, LP, and Rtw Investments, Lp.
View insider buying and selling activity for Stoke Therapeutics.

Shares of STOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of STOK stock can currently be purchased for approximately $29.00.

Stoke Therapeutics has a market capitalization of $963.29 million. The company earns $-32,330,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Stoke Therapeutics employs 44 workers across the globe.

The official website for Stoke Therapeutics is www.stoketherapeutics.com.

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company can be reached via phone at 781-430-8200 or via email at [email protected]